Navigation Links
Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
Date:10/24/2008

ESSEX, United Kingdom, Oct. 24 /PRNewswire-FirstCall/ -- Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo. This result in the primary endpoint of the study is both clinically and statistically highly significant.

A further primary endpoint showed a reduction in the number of migraine headache days. This reduction did not reach statistical significance, probably owing to the small number of patients participating in the trial and, it is thought, because some of the patients suffered a type of migraine aura that is not followed by headache.

The results also showed statistically significant effects on some of the secondary endpoints including the number of attacks of migraine headache and the number of auras followed by any headache. All secondary endpoints were numerically in favor of tonabersat compared with placebo.

Migraine with aura affects around 30 percent of migraine sufferers and is a type of migraine in which the headache is preceded by symptoms such as visual disturbances and abnormalities of speech and hearing. These aura symptoms are generally recognized as being difficult to treat with existing medications.

A total of 31 patients completed the Phase II trial, which was conducted at the Danish Headache Center at Copenhagen's Glostrup University Hospital. The principal investigator in the trial was Professor Jes Olesen, the Danish Headache Center's Director and one of the world's leading authorities on headache.

Under the trial's cross-over design, patients took either tonabersat or placebo once a day for a three-month period after which the treatment regimen was reversed such that those initia
'/>"/>

SOURCE Minster Pharmaceuticals plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
2. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
3. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
4. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
5. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
6. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
10. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
11. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Mich., Dec. 3 Stryker Corporation (NYSE: SYK ) ... to repurchase up to $750 million of its common stock. ... by the Company,s management based on their evaluation of market conditions, ... considerations. Purchases may be made from time to time in ...
... CAMBRIDGE, Mass., Dec. 3, 2009 Raytheon BBN Technologies, a ... has licensed its patented, award-winning stereo digital mammography (SDM) technology ... SDM technology with the Aspire HD FFDM system. Combined with ... stereo images for 3-D viewing. FUJIFILM will display the Raytheon ...
Cached Medicine Technology:Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 2Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 3
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Losing weight can help reduce your risk of cancer if ... effective in lowering that risk, an expert says. Diets ... changes in eating habits and also provide a variety of ... clinical dietitian in the clinical nutrition department at the University ...
... Urinary tract infections are common in women, costing an ... in the United States alone. These infections frequently ... A depletion of vaginal lactobacilli, a type of ... suggests that replenishing these bacteria may be beneficial. Researchers ...
... , cancer scientists Ana Soto and Carlos Sonnenschein pit their ... cancer against the widely accepted Somatic Mutation Theory (SMT) in ... theories have formally opposed each other championed by authors ... forum for discussion. Soto and Sonnenschein, from Tufts University, ...
... , THURSDAY, April 14 (HealthDay News) -- ... target the new organ can develop accelerated narrowing of ... may lead to organ rejection. That,s the finding ... kidney biopsies from 99 kidney transplant patients -- 40 ...
... a statin before having major elective surgery reduces potentially ... an upcoming issue of the Journal of the ... than 230 million major elective surgeries are performed around ... develop kidney injury soon after surgery, often due to ...
... , Thursday, April 14 (HealthDay News) -- Just as the ... world,s languages also originated there and spread across the globe, ... analyzed the phonemes -- distinct units of sound that differentiate ... pattern mirrors that of human genetic diversity. As humans ...
Cached Medicine News:Health News:A Good Diet Includes Many Cancer-Fighting Foods: Expert 2Health News:Statins may protect against kidney complications following elective surgery 2Health News:Human Language Origins Traced to Africa, Study Finds 2
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
PDA version of the best-selling guide....
PDA application contains 15,000+ ICD-9-CM Diagnosis codes....
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003....
Medicine Products: